Cargando…

Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation

BACKGROUND: Novel circulating biomarkers may help in understanding the underlying mechanisms of atrial fibrillation (AF), a challenge for AF management and prevention of cardiovascular (CV) events. Whether glycosylation affects the prognostic value of N-terminal pro-B type natriuretic peptide (NT-pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Staszewsky, Lidia, Meessen, Jennifer M. T. A., Novelli, Deborah, Wienhues-Thelen, Ursula-Henrike, Disertori, Marcello, Maggioni, Aldo P., Masson, Serge, Tognoni, Gianni, Franzosi, Maria Grazia, Lucci, Donata, Latini, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603582/
https://www.ncbi.nlm.nih.gov/pubmed/34798808
http://dx.doi.org/10.1186/s12872-021-02358-y
_version_ 1784601794816507904
author Staszewsky, Lidia
Meessen, Jennifer M. T. A.
Novelli, Deborah
Wienhues-Thelen, Ursula-Henrike
Disertori, Marcello
Maggioni, Aldo P.
Masson, Serge
Tognoni, Gianni
Franzosi, Maria Grazia
Lucci, Donata
Latini, Roberto
author_facet Staszewsky, Lidia
Meessen, Jennifer M. T. A.
Novelli, Deborah
Wienhues-Thelen, Ursula-Henrike
Disertori, Marcello
Maggioni, Aldo P.
Masson, Serge
Tognoni, Gianni
Franzosi, Maria Grazia
Lucci, Donata
Latini, Roberto
author_sort Staszewsky, Lidia
collection PubMed
description BACKGROUND: Novel circulating biomarkers may help in understanding the underlying mechanisms of atrial fibrillation (AF), a challenge for AF management and prevention of cardiovascular (CV) events. Whether glycosylation affects the prognostic value of N-terminal pro-B type natriuretic peptide (NT-proBNP) in AF is still unknown. OBJECTIVES: To test how deglycosylated total NT-proBNP, NT-proBNP and a panel of biomarkers are associated with: (1) recurrent AF, (2) first hospitalization for CV reasons. METHODS: A total of 382 patients of the GISSI-AF trial in sinus rhythm with a history of AF, echocardiographic variables, total NT-proBNP, NT-proBNP and nine additional biomarkers [Total N-terminal pro-B type natriuretic peptide (Total NT proBNP), N-terminal pro-B type natriuretic peptide (NTproBNP), Angiopoietin 2 (Ang2), Bone morphogenic protein-10 (BMP10), Dickkopf-related protein-3 (DKK3), Endothelial cell specific molecule-1 (ESM1), Fatty acid-binding protein 3 (FABP3), Fibroblast growth factor 23 (FGF23), Growth differentiation factor-15 (GDF15), Insulin-like growth factor-binding protein-7 (IGFBP7) and Myosin binding protein C3 (MYPBC3)]. were assayed at baseline, 6 and 12 months under blind conditions in a laboratory at Roche Diagnostics, Penzberg, Germany. The associations between circulating biomarkers and AF at the 6- and 12-month visits, and their predictive value, were assessed in multivariable models with logistic regression analysis and Cox proportional hazards regression analysis. Biomarkers associations were modelled for 1SD increase in their level. RESULTS: Over a median follow-up of 365 days, 203/382 patients (53.1%) had at least one recurrence of AF and 16.3% were hospitalized for CV reasons. Total NT-proBNP, NT-proBNP, Ang2 and BMP10 showed the strongest associations with ongoing AF. Natriuretic peptides also predicted recurrent AF (total NT-proBNP: HR:1.19[1.04–1.36], p = 0.026; NT-proBNP: HR:1.19[1.06–1.35], p = 0.016; Ang2: HR:1.07[0.95–1.20], p = 0.283; BMP10: HR:1.09[0.96–1.25], p = 0.249) and CV hospitalization (total NT-proBNP: HR:1.57[1.29–1.90], p < 0.001 1.63], p = 0.097). CONCLUSIONS: The association of total NT-proBNP with the risk of AF first recurrence was similar to that of NT-proBNP, suggesting no influence of glycosylation. Analogous results were obtained for the risk of first hospitalization for CV reasons. Natriuretic peptides, Ang2 and BMP10 were associated with ongoing AF. Findings from the last two biomarkers point to a pathogenic role of cardiac extracellular matrix and cardiomyocyte growth in the myocardium of the right atrium and ventricle. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-021-02358-y.
format Online
Article
Text
id pubmed-8603582
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86035822021-11-19 Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation Staszewsky, Lidia Meessen, Jennifer M. T. A. Novelli, Deborah Wienhues-Thelen, Ursula-Henrike Disertori, Marcello Maggioni, Aldo P. Masson, Serge Tognoni, Gianni Franzosi, Maria Grazia Lucci, Donata Latini, Roberto BMC Cardiovasc Disord Research BACKGROUND: Novel circulating biomarkers may help in understanding the underlying mechanisms of atrial fibrillation (AF), a challenge for AF management and prevention of cardiovascular (CV) events. Whether glycosylation affects the prognostic value of N-terminal pro-B type natriuretic peptide (NT-proBNP) in AF is still unknown. OBJECTIVES: To test how deglycosylated total NT-proBNP, NT-proBNP and a panel of biomarkers are associated with: (1) recurrent AF, (2) first hospitalization for CV reasons. METHODS: A total of 382 patients of the GISSI-AF trial in sinus rhythm with a history of AF, echocardiographic variables, total NT-proBNP, NT-proBNP and nine additional biomarkers [Total N-terminal pro-B type natriuretic peptide (Total NT proBNP), N-terminal pro-B type natriuretic peptide (NTproBNP), Angiopoietin 2 (Ang2), Bone morphogenic protein-10 (BMP10), Dickkopf-related protein-3 (DKK3), Endothelial cell specific molecule-1 (ESM1), Fatty acid-binding protein 3 (FABP3), Fibroblast growth factor 23 (FGF23), Growth differentiation factor-15 (GDF15), Insulin-like growth factor-binding protein-7 (IGFBP7) and Myosin binding protein C3 (MYPBC3)]. were assayed at baseline, 6 and 12 months under blind conditions in a laboratory at Roche Diagnostics, Penzberg, Germany. The associations between circulating biomarkers and AF at the 6- and 12-month visits, and their predictive value, were assessed in multivariable models with logistic regression analysis and Cox proportional hazards regression analysis. Biomarkers associations were modelled for 1SD increase in their level. RESULTS: Over a median follow-up of 365 days, 203/382 patients (53.1%) had at least one recurrence of AF and 16.3% were hospitalized for CV reasons. Total NT-proBNP, NT-proBNP, Ang2 and BMP10 showed the strongest associations with ongoing AF. Natriuretic peptides also predicted recurrent AF (total NT-proBNP: HR:1.19[1.04–1.36], p = 0.026; NT-proBNP: HR:1.19[1.06–1.35], p = 0.016; Ang2: HR:1.07[0.95–1.20], p = 0.283; BMP10: HR:1.09[0.96–1.25], p = 0.249) and CV hospitalization (total NT-proBNP: HR:1.57[1.29–1.90], p < 0.001 1.63], p = 0.097). CONCLUSIONS: The association of total NT-proBNP with the risk of AF first recurrence was similar to that of NT-proBNP, suggesting no influence of glycosylation. Analogous results were obtained for the risk of first hospitalization for CV reasons. Natriuretic peptides, Ang2 and BMP10 were associated with ongoing AF. Findings from the last two biomarkers point to a pathogenic role of cardiac extracellular matrix and cardiomyocyte growth in the myocardium of the right atrium and ventricle. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-021-02358-y. BioMed Central 2021-11-19 /pmc/articles/PMC8603582/ /pubmed/34798808 http://dx.doi.org/10.1186/s12872-021-02358-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Staszewsky, Lidia
Meessen, Jennifer M. T. A.
Novelli, Deborah
Wienhues-Thelen, Ursula-Henrike
Disertori, Marcello
Maggioni, Aldo P.
Masson, Serge
Tognoni, Gianni
Franzosi, Maria Grazia
Lucci, Donata
Latini, Roberto
Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation
title Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation
title_full Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation
title_fullStr Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation
title_full_unstemmed Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation
title_short Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation
title_sort total nt-probnp, a novel biomarker related to recurrent atrial fibrillation
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603582/
https://www.ncbi.nlm.nih.gov/pubmed/34798808
http://dx.doi.org/10.1186/s12872-021-02358-y
work_keys_str_mv AT staszewskylidia totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation
AT meessenjennifermta totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation
AT novellideborah totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation
AT wienhuesthelenursulahenrike totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation
AT disertorimarcello totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation
AT maggionialdop totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation
AT massonserge totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation
AT tognonigianni totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation
AT franzosimariagrazia totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation
AT luccidonata totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation
AT latiniroberto totalntprobnpanovelbiomarkerrelatedtorecurrentatrialfibrillation